Regend Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $50.3M

  • Investors
  • 12

Regend General Information

Description

Developer of stem cell therapy products and regenerative medicine intended for medical institutions, clinical research organizations, and therapeutic developers. The company is mainly engaged in research and development of regenerative medicine, providing users with interstitial lung disease, assisted reproduction, stem cell storage, and chronic obstructive pulmonary disease treatment solutions.

Contact Information

Website
www.regend.cn
Formerly Known As
Suzhou Jimeirui Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • A2-411
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • A2-411
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215123
  • China
+86 021

Regend Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Regend Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series C) 11-Feb-2026 $50.3M Completed Generating Revenue
9. Later Stage VC 03-Mar-2025 Completed Generating Revenue
8. Secondary Transaction - Private 03-Mar-2025 Completed Generating Revenue
7. Later Stage VC (Series B1) 09-Feb-2025 Completed Generating Revenue
6. Secondary Transaction - Private 23-Mar-2023 Completed Generating Revenue
5. Later Stage VC (Series B) 01-Jan-2022 Completed Generating Revenue
4. Later Stage VC (Series A1) 01-May-2021 Completed Generating Revenue
3. Early Stage VC (Series A) 01-Jul-2020 Completed Generating Revenue
2. Early Stage VC 01-Feb-2017 $3.22M Completed Generating Revenue
1. Seed Round 01-Aug-2015 $3.22M $3.22M Completed Startup
To view Regend’s complete valuation and funding history, request access »

Regend Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hefei Hi-Tech VC Venture Capital Minority
Hefei Industry Investment Group Venture Capital Minority
Hongtai Capital Holdings Venture Capital Minority
Tasly Capital Corporate Venture Capital Minority
Yuze Investment Management Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Regend FAQs

  • When was Regend founded?

    Regend was founded in 2015.

  • Where is Regend headquartered?

    Regend is headquartered in Suzhou, China.

  • What industry is Regend in?

    Regend’s primary industry is Drug Discovery.

  • Is Regend a private or public company?

    Regend is a Private company.

  • What is Regend’s current revenue?

    The current revenue for Regend is .

  • How much funding has Regend raised over time?

    Regend has raised $69.2M.

  • Who are Regend’s investors?

    Hefei Hi-Tech VC, Hefei Industry Investment Group, Hongtai Capital Holdings, Tasly Capital, and Yuze Investment Management are 5 of 12 investors who have invested in Regend.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process